Our Management Team

Management

Dr Catherine Bladen, Chief Operations Officer

Catherine has more than 15 years’ experience in biochemistry research (specifically protein identification, purification and characterization) both in the UK and in the USA. She completed her PhD in 2001 in the Cancer Research Unit at Newcastle University, studying novel proteins involved in p53 independent cancer pathways. From there, Catherine spent 6 years at the Medical College of Georgia (USA) identifying proteins involved in double stranded DNA repair as a consequence of medical radiation exposure (radiotherapy). Catherine then spent 7 years at Leeds University researching the role of DNA repair and oxidative stress in Osteoarthritis. A further two years were then spent at Newcastle University leading a large, multi-national research project identifying mutations leading to Duchenne Muscular Dystrophy in an effort to understand how mutation status and clinical outcomes were connected. Catherine joined Absolute Antibody in 2015 and leads our research and production teams.

Dr Michael Fiebig, Chief Scientific Officer

Dr Michael Fiebig is the Chief Scientific Officer at Absolute Antibody. Michael studied Biochemistry before obtaining his doctoral degree from the University of Oxford. He joined Absolute Antibody in 2014 to develop the recombinant antibody catalog and many underlying technologies, before transitioning into the role of Chief Scientific Officer in 2021.

Dr Jennifer Rossi, Vice President Americas

In her work roles, Jen enjoys merging her scientific background with business planning and strategy. With a BS/MS from Ohio University and a PhD from Brown University, Jen has held roles at Cohesive Technologies (now part of ThermoFisher), Qiagen, BioTrove (acquired by Life Technologies) and Biocius (now part of Agilent). Jen is President of a non-profit organization, the CMA, which supports 1,500 families in her downtown Boston neighborhood of Charlestown. She also supports several canine rescue groups, enjoys being a mentor and is Trustee of the USS Constitution Museum.

Dr Donmienne Leung, Head of Protein Engineering

Donmienne is a pharmaceutical industry veteran with more than 15 years’ experience in antibody discovery, protein engineering and biologics research. During her career, she has co-authored 11 granted patents, including five molecules in clinical trials (Ph I & II) and more than 20 peer-reviewed publications. She received her doctorate in medicinal chemistry from the University of Queensland in 2001 centered on synthesis and evaluation of protease inhibitors, and pursued post-doctoral training at the Scripps Research Institute in chemical biology. In 2005, she joined Lilly/AME to facilitate the establishment of the antibody discovery platform, which became the biotechnology engine for Eli Lilly and Company in San Diego. She was a senior research advisor/group leader where she managed a high-performance team and enabled the discovery and engineering of antibodies to various targets eventuated in clinical studies. She joined Absolute Antibody in 2021 as our Head of Protein Engineering.

Scientific Advisors

Dr Nicholas Hutchings, Chief Technology Officer

Nicholas is an entrepreneur with a background in immunology and proteomics, whose first startup Everest Biotech Ltd made 5000 traditional antibodies for the research market. He studied Biochemistry at the University of Oxford followed by a doctorate at the Sir William Dunn School of Pathology, supervised by Prof Neil Barclay.

Dr Ian Wilkinson

Ian has a scientific background firmly in the engineering and development of therapeutic antibodies. During a UCB-Celltech sponsored PhD at the University of Leicester, Ian solved the first NMR structure of a human antibody fragment (scFv). From there he moved to MedImmune, the biologics arm of AstraZeneca. He worked on a number of antibody and non-antibody early stage therapeutic research projects covering technology validation, drug discovery and optimization. Ian has been with Absolute Antibody since its founding and developed many of the processes that underpin the company’s recombinant antibody services. With a proven track-record of work on the structure-function relationship of various antibody formats, from full-length to scFv, Ian is eager to apply his expertise to even the most challenging antibody engineering projects.